Loading company details...
Explore prior quarterly filings, historical revenue breakdowns, and earnings trends.
Eli Lilly Q3 2026: Sales Surge 39% as Acquired R&D Weighs on Profit Growth
Oct 30, 2026
Read
Eli Lilly Q2 2026: Mounjaro and Zepbound Drive 48% Revenue Growth
Aug 16, 2026
Read
Eli Lilly Q1 2026 Analysis: Mounjaro and Zepbound Drive Record Growth
Apr 30, 2026
Read
Eli Lilly 10-K Analysis: Inside the $65 Billion Cardiometabolic Surge
Feb 17, 2026
Read
Loading interactive diagram…
Actions | Form 10-K 10-Q | Filing Date | Period | Analysis | Revenue | Net Income |
|---|---|---|---|---|---|---|
10-Q View Filing | Oct 29, 2026 | 2026 Q3 | Analysis | $24.4B | $6.45B | |
10-Q View Filing | Aug 5, 2026 | 2026 Q2 | Analysis | $22.97B | $7.09B | |
10-Q View Filing | Apr 30, 2026 | 2026 Q1 | Analysis | $19.8B | $7.4B | |
10-K View Filing | Feb 12, 2026 | 2025 FY | Analysis | $65.18B | $20.64B | |
10-Q View Filing | Oct 30, 2025 | 2025 Q3 | Analysis | $17.6B | $5.58B | |
10-Q View Filing | Aug 7, 2025 | 2025 Q2 | Analysis | $15.56B | $5.66B | |
10-Q View Filing | May 1, 2025 | 2025 Q1 | - | $12.73B | $2.76B | |
10-K View Filing | Feb 19, 2025 | 2024 FY | - | $45.04B | $10.59B | |
10-Q View Filing | Oct 30, 2024 | 2024 Q3 | - | $11.44B | $970.3M | |
10-Q View Filing | Aug 8, 2024 | 2024 Q2 | - | $11.3B | $2.97B | |
10-Q View Filing | Apr 30, 2024 | 2024 Q1 | - | $8.77B | $2.24B | |
10-K View Filing | Feb 21, 2024 | 2023 FY | - | $34.12B | $5.24B | |
10-Q View Filing | Nov 2, 2023 | - | - | - | - | |
10-Q View Filing | Aug 8, 2023 | - | - | - | - | |
10-Q View Filing | Apr 27, 2023 | - | - | - | - | |
10-K View Filing | Feb 22, 2023 | 2022 FY | - | $28.54B | $6.24B | |
10-Q View Filing | Nov 1, 2022 | - | - | - | - | |
10-Q View Filing | Aug 4, 2022 | - | - | - | - | |
10-Q View Filing | Apr 29, 2022 | - | - | - | - | |
10-K View Filing | Feb 23, 2022 | 2021 FY | - | $28.32B | $5.58B | |
10-Q View Filing | Oct 27, 2021 | - | - | - | - | |
10-Q View Filing | Aug 3, 2021 | - | - | - | - | |
10-Q View Filing | Apr 30, 2021 | - | - | - | - | |
10-K View Filing | Feb 17, 2021 | 2020 FY | - | $24.54B | $6.19B | |
10-Q View Filing | Oct 28, 2020 | - | - | - | - | |
10-Q View Filing | Jul 31, 2020 | - | - | - | - | |
10-Q View Filing | May 1, 2020 | - | - | - | - | |
10-K View Filing | Feb 19, 2020 | 2019 FY | - | $22.32B | $8.32B | |
10-Q View Filing | Oct 25, 2019 | - | - | - | - | |
10-Q View Filing | Aug 2, 2019 | - | - | - | - | |
10-Q View Filing | May 2, 2019 | - | - | - | - | |
10-K View Filing | Feb 19, 2019 | 2018 FY | - | $24.56B | $3.23B | |
10-Q View Filing | Nov 6, 2018 | - | - | - | - | |
10-Q View Filing | Jul 25, 2018 | - | - | - | - | |
10-Q View Filing | Apr 27, 2018 | - | - | - | - | |
10-K View Filing | Feb 20, 2018 | 2017 FY | - | $22.87B | -$204.1M | |
10-Q View Filing | Oct 27, 2017 | - | - | - | - | |
10-Q View Filing | Jul 28, 2017 | - | - | - | - | |
10-Q View Filing | May 1, 2017 | - | - | - | - | |
10-K View Filing | Feb 21, 2017 | 2016 FY | - | $21.22B | $2.74B | |
10-Q View Filing | Oct 28, 2016 | - | - | - | - | |
10-Q View Filing | Jul 28, 2016 | - | - | - | - | |
10-Q View Filing | Apr 29, 2016 | - | - | - | - | |
10-K View Filing | Feb 19, 2016 | 2015 FY | - | $19.96B | $2.41B | |
10-Q View Filing | Oct 30, 2015 | - | - | - | - | |
10-Q View Filing | Jul 30, 2015 | - | - | - | - | |
10-Q View Filing | Apr 30, 2015 | - | - | - | - | |
10-K View Filing | Feb 19, 2015 | 2014 FY | - | $19.62B | $2.39B | |
10-Q View Filing | Oct 29, 2014 | - | - | - | - | |
10-Q View Filing | Jul 28, 2014 | - | - | - | - |
Scroll for more